Intellia Therapeutics Inc buy JPMorgan Chase & Co.
Start price
31.03.23
/
50%
€33.87
Target price
31.03.24
€72.55
Performance (%)
-24.45%
End price
01.04.24
€25.59
Summary
This prediction ended on 01.04.24 with a price of €25.59. The price of Intellia Therapeutics Inc has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -24.45%. JPMorgan_Chase___Co_ has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Intellia Therapeutics Inc | 5.857% | 5.857% | -35.535% |
| iShares Core DAX® | 1.280% | 1.320% | 13.605% |
| iShares Nasdaq 100 | -2.457% | -5.192% | 25.941% |
| iShares Nikkei 225® | -2.006% | -1.389% | 8.973% |
| iShares S&P 500 | -0.662% | -1.884% | 23.684% |
Comments by JPMorgan_Chase___Co_ for this prediction
In the thread Intellia Therapeutics Inc diskutieren
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its price target lowered by analysts at JPMorgan Chase & Co. from $82.00 to $79.00. They now have an "overweight" rating on the stock.
Ratings data for NTLA provided by MarketBeat
In the thread Trading Intellia Therapeutics Inc
Die von JPMorgan_Chase___Co_ gewählte maximale Laufzeit wurde überschritten